Redenlab supporting Larimar Therapeutics in Phase 1 SAD Clinical Trial

Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.

Click here to learn more.

Tags: ,

Related Post

Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia

  • Posted on 25 July, 2025
    A new clinical trial has found early evidence that a metabolic therapy could improve outcomes for people with ataxia-telangiectasia (A-T),...
    Read more

    What can speech tell us about pain?

    • Posted on 26 June, 2025
      Pain is deeply personal, yet universally expressed through speech. But what if speech isn’t just a way we describe pain,...
      Read more

      Understanding speech and language in KIF1A-associated neurological disorder

      • Posted on 17 June, 2025
        A new study published in the European Journal of Human Genetics provides the first systematic analysis of speech and language...
        Read more